Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21

Vaccine

Volumn 33, Issue 42, 2015, Pages 5578-5587

  Beck, Zoltan ^a,b   Matyas, Gary R ^b   Jalah, Rashmi ^a,b   Rao, Mangala ^b   Polonis, Victoria R ^b   Alving, Carl R ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Adjuvants; AS01B; HIV CN54 gp140 envelope protein; Liposomes; Monophosphoryl lipid A; QS21

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GLYCOPROTEIN GP 140; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; LIPOSOME; PHOSPHORYL LIPID A; QS 21; VIRUS ENVELOPE PROTEIN; GP140 ENVELOPE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; LIPID A; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; SAPONIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG FORMULATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SPLEEN CELL; TH1 CELL; TH2 CELL; VIRUS NEUTRALIZATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; HIV INFECTIONS; IMMUNOLOGY; SERODIAGNOSIS;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-4; LIPID A; LIPOSOMES; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS; SAPONINS;

EID: 84943454535     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.001     Document Type: Article

References (50)

1. Sessa G., Weissmann G. Phospholipid spherules (liposomes) as a model for biological membranes. J Lipid Res 1968, 9(May (3)):310-318.
2. Bangham A.D., Standish M.M., Watkins J.C. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 1965, 13(Aug (1)):238-252.
3. Alving C.R., Rao M., Steers N.J., Matyas G.R., Mayorov A.V. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Expert Rev Vaccines 2012, 11(6):733-744. 10.1586/erv.12.35.
4. Watson D.S., Endsley A.N., Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012, 30(Mar (13)):2256-2272. 10.1016/j.vaccine.2012.01.070.
5. Perrie Y., Kastner E., Kaur R., Wilkinson A., Ingham A.J. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum Vaccin Immunother 2013, 9(6):1374-1381. 10.4161/hv.24694.
6. Brito L.A., O'Hagan D.T. Designing and building the next generation of improved vaccine adjuvants. J Control Release 2014, 190(Sep):563-579. 10.1016/j.jconrel.2014.06.027.
7. Schwendener R.A. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2014 Nov, 2(6):159-182. 10.1177/2051013614541440.
8. Banerji B., Alving C.R. Lipid A from endotoxin: antigenic activities of purified fractions in liposomes. J Immunol 1979, 123(Dec (6)):2558-2562.
9. Alving C.R. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991, 140(Jun (1)):1-13.
10. Fries L.F., Gordon D.M., Richards R.L., Egan J.E., Hollingdale M.R., Gross M., et al. Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 1992 Jan 1, 89(1):358-362.
11. Alving C.R., Koulchin V., Glenn G.M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 1995, 145(June):5-31.
12. Alving C.R. Liposomal vaccines: clinical status and immunological presentation for humoral and cellular immunity. Ann N Y Acad Sci 1995, 754(May):143-152.
13. Alving C.R. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002, 20(May (Suppl 3)):S56-S64.
14. Matyas G.R., Muderhwa J.M., Alving C.R. Oil-in-water liposomal emulsions for vaccine delivery. Methods Enzymol 2003, 373:34-50.
15. Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(Oct (5)):723-739.
16. Garcon NM, Friede M. Vaccines containing a saponin and a sterol. International patent application PCT/EP96/01464, International publication number WO 96/33739, 1996.
17. Vandepapeliere P. Vaccine compositions comprising a saponin adjuvant. US patent application No. 13/020,045, Publication No. US20/0206758 (2011).
18. Paepenmüller T., Müller-Goymann C.C. Influence of Quil A on liposomal membranes. Int J Pharm 2014, 475(Nov (1-2)):138-146. 10.1016/j.ijpharm.2014.08.007.
19. Waite D.C., Jacobson E.W., Ennis F.A., Edelman R., White B., Kammer R., et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001, 19(Jul (28-29)):3957-3967.
20. Mbawuike I., Zang Y., Couch R.B. Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant. Vaccine 2007, 25(Apr (17)):3263-3269.
21. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10(4):471-486.
22. Beck Z., Matyas G.R., Alving C.R. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim Biophys Acta 2015, 1848(3):775-780. 10.1016/j.bbamem.2014.12.005.
23. Katinger D., Jeffs S., Altmann F., Cope A., McKay P., Almond N., et al. CN54gp140: product characteristics, preclinical and clinical use-recombinant glycoprotein for HIV immunization. Retrovirology 2012, 9(Suppl 2):P351.
24. Cranage M.P., Fraser C.A., Cope A., McKay P.F., Seaman M.S., Cole T., et al. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation. Vaccine 2011, 29(Feb (7)):1421-1430. 10.1016/j.vaccine.2010.12.034.
25. Pattacini L., Mize G.J., Graham J.B., Fluharty T.R., Graham T.M., Lingnau K., et al. A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PLoS ONE 2012, 7(7):e42163. 10.1371/journal.pone.0042163.
26. Luo Z., Ren L., Zheng Y., Qi Z., Liang H., Liu Y., et al. Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination. Vaccine 2012, 30(Aug (36)):5316-5323. 10.1016/j.vaccine.2012.06.053.
27. Hassall M., Page M., Robinson M., Jeffs S., Jones I., Chen H., et al. The production, characterisation and application of monoclonal antibodies generated by immunisation with HIV-1C clade RGP140 envelope protein. J Virol Methods 2013, 194(Dec (1-2)):89-93. 10.1016/j.jviromet.2013.08.011.
28. Knudsen M.L., Ljungberg K., Tatoud R., Weber J., Esteban M., Liljeström P. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia ankara (MVA) or with HIV gp140 protein antigen. PLOS ONE 2015, 10(2):e0117042. 10.1371/journal.pone.0117042.
29. Zlatkis A., Zak B., Boyle A.J. A new method for the direct determination of serum cholesterol. J Lab Clin Med 1953, 41(3):486-492.
30. Glenn G.M., Rao M., Richards R.L., Matyas G.R., Alving C.R. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. Immunol Lett 1995, 47(Jul-Aug (1-2)):73-78.
31. Rao M., Bray M., Alving C.R., Jahrling P., Matyas G.R. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells. J Virol 2002, 76(Sep (18)):9176-9185.
32. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., et al. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J Virol 2007, 81(Feb (4)):2087-2091.
33. Alving C.R., Conrad D.H., Gockerman J.P., Gibbs M.B., Wirtz G.H. Vitamin A in liposomes, inhibition of complement binding and alteration of membrane structure. Biochim Biophys Acta 1975, 394(Jun (2)):157-165.
34. Shah R.R., O'Hagan D.T., Amiji M.M., Brito L.A. The impact of size on particulate vaccine adjuvants. Nanomedicine (Lond) 2014, 9(Dec (17)):2671-2681. 10.2217/nnm.14.193.
35. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38(5):1404-1413. 10.1002/eji.200737984.
36. Beutler B., Rietschel E.T. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003.
37. Brandenburg K., Richter W., Koch M.H., Meyer H.W., Seydel U. Characterization of the nonlamellar cubic and HII structures of lipid A from Salmonella enterica serovar Minnesota by X-ray diffraction and freeze-fracture electron microscopy. Chem Phys Lipids 1998, 91(1):53-69.
38. Vogel F.R., Powell M.F. A compendium of vaccine adjuvants and excipients. Vaccine design. The subunit and adjuvant approach 1995, 141-228. Plenum Press, New York, NY. M.F. Powell, M.J. Newmann (Eds.).
39. Matyas G.R., Wieczorek L., Beck Z., Ochsenbauer-Jambor C., Kappes J.C., Michael N.L., et al. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS 2009, 23(Oct (16)):2069-2077. 10.1097/QAD.0b013e32832faea5.
40. Richardson E.C., Banerji B., Seid R.C., Levin J., Alving C.R. Interactions of lipid A and liposome-associated lipid A with Limulus polyphemus amoebocytes. Infect Immun 1983, 39(3):1385-1391.
41. Richards R.L., Swartz G.M., Schultz C., Hayre M.D., Ward G.S., Ballou W.R., et al. Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. Vaccine 1989, 7(Dec (6)):506-512.
42. Mann J.F., McKay P.F., Fiserova A., Klein K., Cope A., Rogers P., et al. Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes. J Virol 2014, 88(12):6959-6969. 10.1128/JVI.00183-14.
43. Pearse M.J., Drane D. ISCOMATRIX® adjuvant for antigen delivery. Adv Drug Deliv Rev 2005, 57(Jan (3)):465-474.
44. Myschik J., Lendemans D.G., McBurney W.T., Demana P.H., Hook S., Rades T. On the preparation, microscopic investigation and application of ISCOMs. Micron 2006, 37(8):724-734.
45. Bengtsson K.L., Karlsson K.H., Magnusson S.E., Reimer J.M., Stertman L. Matrix-M adjuvant: enhancing immune responses by 'setting the stage' for the antigen. Expert Rev Vaccines 2013, 12(8):821-823. 10.1586/14760584.2013.814822.
46. Kersten G.F., Crommelin D.J. Liposomes and ISCOMS as vaccine formulations. Biochim Biophys Acta 1995, 1241(Jul (2)):117-138.
47. Klein S.L., Jedlicka A., Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010, 10(5):338-349. 10.1016/S1473-3099(10)70049-9.
48. Alving C.R., Peachman K.K., Rao M., Reed S.G. Adjuvants for human vaccines. Curr Opin Immunol 2012, 24(Jun (3)):310-315. 10.1016/j.coi.2012.03.008.
49. Finkelman F.D., Holmes J., Katona I.M., Urban J.F., Beckmann M.P., Park L.S., et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990, 8:303-333.
50. Markine-Goriaynoff D., van der Logt J.T., Truyens C., Nguyen T.D., Heessen F.W., Bigaignon G., et al. IFN-gamma-independent IgG2a production in mice infected with viruses and parasites. Int Immunol 2000, 12(2):223-230.